Browsing Tag
Eli Lilly and Company
178 posts
Lilly bags Zepbound FDA approval for obesity treatment
The U.S. Food and Drug Administration has granted approval to Eli Lilly’s Zepbound (tirzepatide) injection, making it the…
Eli Lilly announces $1.4bn acquisition of POINT Biopharma in radiopharmaceutical domain
Eli Lilly and Company (NYSE: LLY) is set to acquire POINT Biopharma Global, Inc. (NASDAQ: PNT), a leading…
Jardiance receives FDA approval to tackle kidney disease and cardiovascular risks
The U.S. Food and Drug Administration (FDA) has granted approval for Jardiance (empagliflozin) 10 mg tablets, a significant…
Eli Lilly receives FDA response letter for eczema treatment lebrikizumab
Eli Lilly and Company (NYSE: LLY) has announced a recent development regarding its biologic license application (BLA) for…
Phase 3 LIBRETTO-531 trial : Lilly’s Retevmo meets primary endpoint of PFS
Eli Lilly and Company (NYSE: LLY) unveiled exceptional results from their LIBRETTO-531 study of Retevmo (selpercatinib), setting a…
Lilly expands portfolio with $1.9bn acquisition of Versanis Bio
In a move marking a significant expansion in the biopharmaceutical sector, Eli Lilly and Company (Lilly) has successfully…
Lilly wraps up Sigilon Therapeutics acquisition to amplify Type 1 diabetes research
Eli Lilly and Company (Lilly) has formally announced the culmination of its $309.6 million takeover of biopharma trailblazer,…
Eli Lilly completes $2.4bn acquisition of DICE Therapeutics
Eli Lilly and Company (Lilly) has finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE) for $2.4 billion,…
Eli Lilly Q2 2023 financial results highlight robust 28% revenue growth
Eli Lilly and Company (NYSE: LLY) unveiled their Q2 2023 financials, showcasing a 28% revenue enhancement, predominantly driven…
LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC
Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the…